Immunic’s (IMUX) “Outperform” Rating Reiterated at Leerink Partners

Leerink Partners restated their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a report released on Monday morning, Marketbeat reports. The firm currently has a $5.00 price objective on the stock. A number of other analysts have also recently weighed in on the stock. B. Riley began coverage on shares of Immunic […]